Hong Kong Stock Market Flash | LIVZON PHARMA (01513) Climbs Nearly 3% Following Official Approval of Leikangchita Monoclonal Antibody Injection
Stock News
Sep 07
LIVZON PHARMA (01513) shares rose nearly 3% during trading, last up 2.55% at HK$20.90, with turnover reaching HK$15.2846 million.
According to a recent announcement on LIVZON PHARMA's official WeChat account, the company's first innovative biologic in China targeting the IL-17A/F dual pathway, Libeitan® (generic name: Leikangchita monoclonal antibody injection), has officially received market approval.
Guosen Securities noted that Leikangchita (an IL-17A/F antibody) demonstrated superior efficacy compared head-to-head with secukinumab in the treatment of psoriasis, and the Phase 3 clinical trial for ankylosing spondylitis has also yielded favorable results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.